Zynerba’s cannabis based gel for epilepsy fails study

Reuters August 7, 2017 Medical, Research

(Reuters) – Zynerba Pharmaceuticals said on Monday its experimental synthetic cannabis-based gel failed to induce a statistically significant reduction in seizures in a mid-stage study involving epilepsy patients.

Zynerba’s ZYN002 gel is being studied in adults who have epilepsy with focal seizures.

It is also being studied in osteoarthritis patients and in children with Fragile X Syndrome, a genetic condition that causes a range of developmental problems.

Reporting by Natalie Grover in Bengaluru; Editing by Martina D’Couto

Continue reading at Reuters.com

Tags

About Reuters

Since 1850, we have experimented, invented, and created content and news solutions to become the world’s leading international news agency. Always at the forefront of real-time breaking news and high-impact global multimedia content, we are constantly innovating our products and services to meet your business needs. Whether we are serving broadcasters, publishers, brands, agencies, or direct to consumers, Reuters provides award-winning coverage of the day’s most important topics, including: business, finance, politics, sports, entertainment, technology, health, environment, and much more.

Leave a Reply

Your email address will not be published. Required fields are marked *

Designed by indo.media